Treats angina pectoris due to coronary artery disease. ANDA 75147, held by Ani Pharms. Isosorbide Mononitrate.
As of Nov 16, 2026, ANDA 75147 (Isosorbide Mononitrate), held by Ani Pharms, was first approved by FDA on Nov 27, 1998, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Isosorbide Mononitrate Tablets USP are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 27, 1998 | Original application | Approved |
| Isosorbide Mononitrate20MG · tablet;oral | Isosorbide Mononitrate | Rx |
| Isosorbide Mononitrate10MG · tablet;oral | Isosorbide Mononitrate | Rx |
| Jun 7, 2000 | Supplement 3Labeling | Approved | None posted |
| Mar 20, 2000 | Supplement 2Labeling | Approved | None posted |
| Sep 23, 1999 | Supplement 1Manufacturing | Approved | None posted |
| Nov 27, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters